ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

SAN FRANCISCO, Nov. 19, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises ImmunityBio, Inc. investors that the firm is investigating potential legal claims relating to the company's unsuccessful efforts in 2023 to secure regulatory approval for its flagship product Anktiva, designed to treat bladder cancer. Current shareholders are encouraged to contact the firm.

On June 20, 2024, Judge Gonzalo P. Curiel of the U.S. District Court for the Southern District of California issued an order denying in part a motion to dismiss a class action complaint filed against ImmunityBio and certain of its executive officers. There, it is alleged that biotechnology company ImmunityBio intentionally misled investors between March 2021 and May 2023 about the prospects of obtaining U.S. Food and Drug Administration approval for Anktiva by concealing known recordkeeping, quality control, and sanitation problems at its contract manufacturer. When the truth was revealed in May 2023, ImmunityBio's stock fell 55%.

The Schubert firm is investigating potential wrongdoing by ImmunityBio's officers and directors in connection with these allegations.

If you own stock in ImmunityBio and want additional information about your legal rights, please visit our website at https://www.classactionlawyers.com/immunitybio.

About Schubert Jonckheer & Kolbe LLP

Schubert Jonckheer & Kolbe represents shareholders, employees, and consumers in class actions against corporate defendants, as well as shareholders in derivative actions against their officers and directors. The firm is based in San Francisco, and with the help of co-counsel, litigates cases nationwide.

Contact
Dustin L. Schubert
Schubert Jonckheer & Kolbe LLP
[email protected]
Tel: (415) 788-4220

SOURCE Schubert Jonckheer & Kolbe LLP